Stocks in News: Halozyme Therapeutics, Inc. (NASDAQ:HALO), IRIDEX Corporation (NASDAQ:IRIX), Commerce Bancshares, Inc. (NASDAQ:CBSH), Revance Therapeutics, Inc. (NASDAQ:RVNC),

Halozyme Therapeutics, Inc. (NASDAQ:HALO)‘s stock had its “hold” rating reissued by equities research analysts at Liberum Capital in a report issued on Monday, StockTargetPrices.com reports. They currently have a $0.21 target price on the stock. Liberum Capital’s target price points to a potential upside of 421.74% from the stock’s current price.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) belongs to Healthcare sector. Its net profit margin is -23.90% and weekly performance is -10.04%. On last trading day company shares ended up at $10.84. Halozyme Therapeutics, Inc. (NASDAQ:HALO) distance from 50-day simple moving average (SMA50) is 11.96%.
 
IRIDEX Corporation (NASDAQ:IRIX) announced that it will release its first quarter 2016 financial results after the market closes on Thursday, May 5, 2016. 

IRIDEX Corporation (NASDAQ:IRIX) shares advanced 3.35% in last trading session and ended the day at $11.41. IRIX Gross Margin is 47.80% and its return on assets is 1.10%. IRIDEX Corporation (NASDAQ:IRIX) quarterly performance is 20.36%.
 
Commerce Bancshares, Inc. (NASDAQ:CBSH), a molecular diagnostics company specializing in DNA-based testing services for pre-implantation genetic diagnostics and screening, miscarriage analysis, prenatal and pediatric diagnostics, notes that Blue Cross Blue Shield of Arkansas and Blue Cross Blue Shield of Tennessee have revised their medical policies to include reimbursement for chromosomal microarray analysis of fetal tissue for the evaluation of recurrent pregnancy loss

On 28 April, Commerce Bancshares, Inc. (NASDAQ:CBSH) shares fell -0.97% and was closed at $46.85. CBSH EPS growth in last 5 year was -34.20%. Commerce Bancshares, Inc. (NASDAQ:CBSH) year to date (YTD) performance is 10.69%.

Revance Therapeutics, Inc. (NASDAQ:RVNC) CEO Dan Brown and IR Sr. Director Jeanie Herbert. The analyst thinks RVNC’s pipeline is underappreciated and expects five launches over five years beginning in ’19 which should drive upward earnings revisions and multiple expansion.

Revance Therapeutics, Inc. (NASDAQ:RVNC) ended the last trading day at $18.79. Company weekly volatility is calculated as 4.03% and price to cash ratio as 2.04. Revance Therapeutics, Inc. (NASDAQ:RVNC) showed a weekly performance of -4.28%.
CombiMatrix Corporation (NASDAQ:CBMX) announces that it will release financial results for the three months ended March 31, 2016 after market close on Wednesday, May 4, 2016. 

CombiMatrix Corporation (NASDAQ:CBMX) shares advanced 2.92% in last trading session and ended the day at $3.17. CBMX Gross Margin is 46.00% and its return on assets is -74.90%. CombiMatrix Corporation (NASDAQ:CBMX) quarterly performance is -54.06%.

Leave a Reply

Your email address will not be published. Required fields are marked *